Imcyse
is a biopharmaceutical company that develops and commercializes immunotherapies for the treatment of chronic autoimmune diseases... Read moreImcyse
is a biopharmaceutical company that develops and commercializes immunotherapies for the treatment of chronic autoimmune diseases... Read more
News
Sep 13, 2023
FinanzNachrichten
Imcyse: Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis
Jun 22, 2023
FinanzNachrichten
Imcyse: EQS-News: Imcyse SA: Imcyse joins CLAIMS, a European Health Initiative Project to Make Data-Driven Precision Medicine a Reality for Patients with Multiple Sclerosis
Mar 02, 2023
Clinical Trials Arena
Imcyse: Imcyse concludes enrolment in Type 1 diabetes therapy trial
Apr 13, 2022
GlobalNewswire
Press Release: Imcyse : Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of Imotope IMCY-0141 for Multiple Sclerosis
Mar 14, 2022
FinanzNachrichten
Imcyse: DGAP-News: Imcyse SA: Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference
Jan 13, 2022
centralcharts
Press Release: Imcyse : DGAP-News: Imcyse SA: Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study
Jun 24, 2021
centralcharts
Press Release: Imcyse : DGAP-News: Imcyse appoints new Scientific Advisory Board and opens new laboratories for next phase of growth
Feb 04, 2021
BioSpace
ImCyse: Pfizer Renews Partnership for Next-Gen Approach to Autoimmune Disease
Feb 03, 2021
Accesswire
Press Release: ImCyse : Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes
Feb 03, 2021
FinanzNachrichten
ImCyse: Imcyse Enters into Research Collaboration and License Agreement for its Imotope Technology with Pfizer in Rheumatoid Arthritis
